Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11336152 | 0.91 | TSHR (0.43) | TSHRALDH1A1PLA2G2CSPHK2SPHK1 | |
| SCHEMBL8410285 | 0.86 | — | — | |
| SCHEMBL32669043 | 0.83 | HSD17B10 (0.50) | TSHRALDH1A1PLA2G2CSPHK1LMNA | |
| SCHEMBL15536994 | 0.78 | ALDH1A1 (0.36) | TSHRALDH1A1PLA2G2CLMNAUSP2 | |
| SCHEMBL16026686 | 0.77 | CA1 (0.42) | TSHRALDH1A1PLA2G2CSPHK1LMNA | |
| SCHEMBL891976 | 0.77 | TSHR (0.45) | TSHRALDH1A1LMNAMAPTLPAR3 | |
| SCHEMBL3962044 | 0.77 | SPHK1 (0.38) | ALDH1A1SPHK2SPHK1USP2CYP3A4 | |
| SCHEMBL11858528 | 0.77 | SPHK1 (0.42) | ALDH1A1PLA2G2CSPHK2SPHK1USP2 | |
| SCHEMBL3119793 | 0.75 | — | — | |
| SCHEMBL32669046 | 0.75 | HSD17B10 (0.47) | TSHRALDH1A1PLA2G2CSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096317-A1 | REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| EP-1251128-B1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER LAMBERT CO (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6828341-B2 | Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders | WARNER-LAMBERT COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | GLRB, GRIN1, GRIN2B | TSHR 1637/4885ALDH1A1 1057/4885PLA2G2C 4295/4885 |
| US-20130096317-A1 | REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS | POF1B, PHF2, ADH1C | TSHR 4242/4885ALDH1A1 14/4885PLA2G2C 4115/4885 |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | TSHR 3145/4885ALDH1A1 445/4885PLA2G2C 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.